Table 4 Efficacy of selective decontamination for ESBL-E fecal carriage among ICU patients
Year | Authors | Design | Decontamination | N | Outcome | Brief results |
|---|---|---|---|---|---|---|
2018 | Wittekamp et al. [46] | Randomized controlled trial | CHX 2% SOD by mouthpaste (colistin, tobramycin, nystatin) SDD by the same mouthpaste and gastrointestinal suspension) | 8665 | ICU-acquired ESBL-E BSI | aHR vs baseline: CHX 1.13 (95% CI 0.68–1.88) SOD 0.89 (95% CI 0 .55–1.45) SDD 0.70 (95% CI 0.43–1.14) |
2016 | Camus et al. [44] | Observational Before-after | SDD by as follows: Colistin Tobramycin Amphotericin B | 5250 | Rates of acquired infections caused by AGNB Rates of ESBL-E fecal carriage acquisition | Diminution of the incidence rate of acquired infections caused by AGNB (1.59 vs 5.43 per 1000 patient-days, p < 0.001) Diminution of the acquisition rate of ESBL-E fecal carriage (OR = 0.94 [0.88–1.00], p = 0.04) |
2005 | Troché et al. [43] | Prospective observational cohort study | SDD by 2 among the following: Erythromycin Neomycin Polymyxin E | 2235 | Rates of ESBL-E fecal carriage acquisition | Diminution of the acquisition rate of ESBL-E fecal carriage from 5.5 cases per 1000 patient-days during the first 3 years to 1.9 cases during the last 3 years (p < 0.05) |
1998 | Decré et al. [45] | Prospective controlled cohort study | SDD by as follows: Erythromycin Polymyxin E | 65 | Incidence and infection with ESBL- K. pneumoniae | Selective digestive decolonization failed to reduce the incidence of acquisition of ESBL-producing K. pneumoniae |